Standard screening methods underreport AAV-mediated transduction and gene editing

被引:0
|
作者
Jonathan F. Lang
Sushila A. Toulmin
Kasey L. Brida
Laurence C. Eisenlohr
Beverly L. Davidson
机构
[1] The Children’s Hospital of Philadelphia,The Department of Pathology and Laboratory Medicine, Perelman School of Medicine
[2] University of Pennsylvania,undefined
来源
Nature Communications | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Conventional methods to discern adeno-associated virus (AAV) vector transduction patterns are based on high, stable expression of a reporter gene. As a consequence, conventionally described tropisms omit cell types that undergo transient transduction, or have low but undetectable levels of reporter expression. This creates a blind spot for AAV-based genome editing applications because only minimal transgene expression is required for activity. Here, we use editing-reporter mice to fill this void. Our approach sensitively captures both high and low transgene expression from AAV vectors. Using AAV8 and other serotypes, we demonstrate the superiority of the approach in a side-by-side comparison with traditional methods, demonstrate numerous, previously unknown sites of AAV targeting, and better predict the gene editing footprint after AAV-CRISPR delivery. We anticipate that this system, which captures the full spectrum of transduction patterns from AAV vectors in vivo, will be foundational to current and emerging AAV technologies.
引用
收藏
相关论文
共 50 条
  • [41] AAV-Mediated Gene Therapy for the Treatment of Retinal Diseases
    Rolling, Fabienne
    CURRENT GENE THERAPY, 2010, 10 (05) : 318 - U4
  • [42] Homologous recombination is required for AAV-mediated gene targeting
    Vasileva, Ana
    Linden, R. Michael
    Jessberger, Rolf
    NUCLEIC ACIDS RESEARCH, 2006, 34 (11) : 3345 - 3360
  • [43] Cytostatic drugs enhance AAV-mediated gene targeting
    Rahman, Shamim
    Gellhaus, Katharina
    Montazami, Kaweh
    Heilbronn, Regine
    Cathomen, Toni
    HUMAN GENE THERAPY, 2009, 20 (11) : 1501 - 1502
  • [44] Emerging Issues in AAV-Mediated In Vivo Gene Therapy
    Colella, Pasqualina
    Ronzitti, Giuseppe
    Mingozzi, Federico
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2018, 8 : 87 - 104
  • [45] Recombinant AAV-mediated gene therapy for Phenylketonuria.
    Charron, CE
    Reyes, L
    Embury, JE
    Steele, HA
    Ross, K
    Lewin, AS
    Flotte, TR
    Laipis, PJ
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) : 201 - 201
  • [46] AAV-Mediated Ribozyme Gene Therapy for Ocular Herpes
    Barrozo, Enrico R.
    Watson, Zachary L.
    Washington, Shannan D.
    Phelan, Dane M.
    Tuli, Sonal S.
    Lewin, Alfred S.
    Neumann, Donna M.
    Bloom, David C.
    MOLECULAR THERAPY, 2019, 27 (04) : 263 - 263
  • [47] Direct AAV-mediated gene delivery to the temporomandibular joint
    Dai, Juan
    Bakr, A.
    Rabie, M.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 2212 - 2220
  • [48] AAV-Mediated Gene Therapy for GBA-PD
    Ayloo, Swathi
    Ryu, Jae
    Chou, Shih-Ching
    Miller, Charles
    Lacson, Tracy
    Gonclaves, Mariana
    Guo, Lilu
    Naas, Shelley
    Elmer, Bradford
    O'Riordan, Catherine
    Goulet, Martin
    Mueller, Christian
    Ramachandran, Shyam
    MOLECULAR THERAPY, 2024, 32 (04) : 529 - 529
  • [49] AAV-mediated Gene therapy for GBA-PD
    Ayloo, S.
    Ryu, J.
    Chou, S.
    Miller, C.
    Blatnik, L.
    Wischhof, E.
    Bu, J.
    McCarty, W.
    Guo, L.
    Nass, S.
    O'Riordan, C.
    Elmer, B.
    Mueller, C.
    Ramachandran, S.
    MOVEMENT DISORDERS, 2024, 39 : S381 - S381
  • [50] Prospects of AAV-mediated gene therapy for neuromuscular disease
    Voit, T.
    NEUROMUSCULAR DISORDERS, 2010, 20 (9-10) : 638 - 638